Medipost's Cartistem Begins U.S. Phase 3, Doses First Patient
5h agoen
Source
Seoul Economic DailyMedipost's Cartistem Begins U.S. Phase 3, Doses First Patientsedaily.comMedipost has dosed its first patient in the U.S. Phase 3 trial of Cartistem, its knee osteoarthritis stem cell therapy, targeting 300 patients across 70+ sites in the U.S. and Canada.
You might also wanna read
Stanford Researchers Develop Injection That Regenerates Knee Cartilage and Prevents Arthritis
Stanford Medicine researchers have developed an anti-aging injection that regenerates knee cartilage and prevents arthritis by blocking an a
scitechdaily.com·6mo ago
First Successful In-Utero Stem Cell Therapy for Spina Bifida Shows Safety in Phase 1 Trial
UC Davis Health researchers have successfully performed the world's first in-utero stem cell therapy for spina bifida repair, combining feta

Columbia University selects Made Scientific as manufacturing partner for biologic knee replacement program
bioprocessintl.com·1mo ago
Stanford study finds treatment that regrows knee cartilage and reverses arthritis in mice
Stanford Medicine researchers have discovered that blocking a protein linked to aging can restore lost knee cartilage in older mice and prev
sciencedaily.com·18d ago
Colorado researchers develop regenerative injection that reverses osteoarthritis in animal studies
Researchers from the University of Colorado Boulder, CU Anschutz, and Colorado State University have developed experimental treatments for o
sciencedaily.com·6d ago
Experimental Osteoarthritis Therapies Show Joint Healing in Animal Studies, Clinical Trials Expected Within 18 Months
Researchers have developed experimental osteoarthritis therapies that show promise in animal studies, using regenerative injections and biom
scitechdaily.com·1mo ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.